Literature DB >> 24084262

Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans.

Anne Chauvat1, Nadine Benhamouda2, Alain Gey2, Francois M Lemoine3, Staffan Paulie4, Fabrice Carrat5, Marie-Lise Gougeon6, Flore Rozenberg7, Anne Krivine7, Mustapha Cherai3, Paul Lehmann8, Françoise Quintin-Colonna9, Odile Launay10, Eric Tartour11.   

Abstract

The type of T cell polarization and simultaneous production of multiple cytokines have been correlated with vaccine efficacy. ELISpot is a T cell detection technique optimized for the measurement of a secreted cytokine at the single cell level. The FluoroSpot assay differs from ELISpot by the use of multiple fluorescent-labeled anticytokine detection antibodies, allowing optimal measurement of multiple cytokines. In the present study, we show that an IFNγ/IL-10 FluoroSpot assay is more sensitive than flow cytometry to detect Tr1 regulatory T cells, an immunosuppressive T cell population characterized by the production of IL-10 and IFNγ. As many tolerogenic vaccines are designed to induce these Tr1 cells, this FluoroSpot test could represent a standard method for the detection of these cells in the future. The use of an IFNγ/IL-2 FluoroSpot assay during influenza vaccine monitoring showed that the influenza-specific IL-2-producing T-cell response was the dominant response both before and after vaccine administration. This study therefore questions the rationale of using the single-color IFNγ ELISpot as the standard technique to monitor vaccine-specific T-cell response. Using this same test, a trend was also observed between baseline levels of IFNγ T cell response and T cell vaccine response. In addition, a lower IFNγ+IL-2+ T-cell response after vaccine was observed in the group of patients treated with TNFα inhibitors (P=0.08). This study therefore supports the use of the FluoroSpot assay due to its robustness, versatility and the complementary information that it provides compared with ELISpot or flow cytometry to monitor vaccine-specific T-cell responses.

Entities:  

Keywords:  FluoroSpot; IL-10 suppressive T cells; T cell response; immunomonitoring; influenza vaccine

Mesh:

Substances:

Year:  2013        PMID: 24084262      PMCID: PMC4181035          DOI: 10.4161/hv.26593

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  72 in total

1.  Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity.

Authors:  Omid Akbari; Gordon J Freeman; Everett H Meyer; Edward A Greenfield; Tammy T Chang; Arlene H Sharpe; Gerald Berry; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Nat Med       Date:  2002-07-29       Impact factor: 53.440

2.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

Authors:  Grazia Galli; Duccio Medini; Erica Borgogni; Luisanna Zedda; Monia Bardelli; Carmine Malzone; Sandra Nuti; Simona Tavarini; Chiara Sammicheli; Anne K Hilbert; Volker Brauer; Angelika Banzhoff; Rino Rappuoli; Giuseppe Del Giudice; Flora Castellino
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

3.  Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.

Authors:  J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench
Journal:  J Viral Hepat       Date:  2010-07-05       Impact factor: 3.728

Review 4.  Hallmarks of CD4 T cell immunity against influenza.

Authors:  K K McKinstry; T M Strutt; S L Swain
Journal:  J Intern Med       Date:  2011-03-25       Impact factor: 8.989

5.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

Review 6.  Regulatory T cells and allergic disease.

Authors:  Kayhan T Nouri-Aria; Stephen R Durham
Journal:  Inflamm Allergy Drug Targets       Date:  2008-12

Review 7.  The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.

Authors:  M Zeremski; L M Petrovic; A H Talal
Journal:  J Viral Hepat       Date:  2007-10       Impact factor: 3.728

8.  The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer.

Authors:  Cécile Badoual; Grégory Bouchaud; Nour El Houda Agueznay; Erwan Mortier; Stéphane Hans; Alain Gey; Fahima Fernani; Séverine Peyrard; Pierre Laurent -Puig; Patrick Bruneval; Xavier Sastre; Ariane Plet; Laure Garrigue-Antar; Françoise Quintin-Colonna; Wolf H Fridman; Daniel Brasnu; Yannick Jacques; Eric Tartour
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

9.  Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.

Authors:  Andrew G Jarnicki; Helen Conroy; Corinna Brereton; Graham Donnelly; Deirdre Toomey; Kevin Walsh; Cheryl Sweeney; Olive Leavy; Jean Fletcher; Ed C Lavelle; Padraic Dunne; Kingston H G Mills
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

10.  Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance.

Authors:  Manuela Battaglia; Angela Stabilini; Elena Draghici; Silvia Gregori; Cristina Mocchetti; Ezio Bonifacio; Maria-Grazia Roncarolo
Journal:  Diabetes       Date:  2006-01       Impact factor: 9.461

View more
  7 in total

1.  Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination.

Authors:  Mladen Jergović; Jennifer L Uhrlaub; Makiko Watanabe; Christine M Bradshaw; Lisa M White; Bonnie J LaFleur; Taylor Edwards; Ryan Sprissler; Michael Worobey; Deepta Bhattacharya; Janko Nikolich-Žugich
Journal:  Nat Commun       Date:  2022-05-24       Impact factor: 17.694

2.  Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab.

Authors:  Andreas Tolf; Anna Wiberg; Malin Müller; Faisal Hayat Nazir; Ivan Pavlovic; Ida Laurén; Sara Mangsbo; Joachim Burman
Journal:  JAMA Netw Open       Date:  2022-05-02

Review 3.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Authors:  Pierre Combe; Eleonore de Guillebon; Constance Thibault; Clémence Granier; Eric Tartour; Stéphane Oudard
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

Review 4.  Measuring single-cell protein secretion in immunology: Technologies, advances, and applications.

Authors:  Olivia T M Bucheli; Ingibjörg Sigvaldadóttir; Klaus Eyer
Journal:  Eur J Immunol       Date:  2021-04-01       Impact factor: 5.532

5.  Triple Cytokine FluoroSpot Analysis of Human Antigen-Specific IFN-γ, IL-17A and IL-22 Responses.

Authors:  Tomas Dillenbeck; Eva Gelius; Jenny Fohlstedt; Niklas Ahlborg
Journal:  Cells       Date:  2014-11-27       Impact factor: 6.600

Review 6.  Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.

Authors:  Matthieu Van Tilbeurgh; Katia Lemdani; Anne-Sophie Beignon; Catherine Chapon; Nicolas Tchitchek; Lina Cheraitia; Ernesto Marcos Lopez; Quentin Pascal; Roger Le Grand; Pauline Maisonnasse; Caroline Manet
Journal:  Vaccines (Basel)       Date:  2021-06-01

7.  Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity.

Authors:  Sidhartha Chaudhury; Elizabeth H Duncan; Tanmaya Atre; Sheetij Dutta; Michele D Spring; Wolfgang W Leitner; Elke S Bergmann-Leitner
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.